L'impact factor dei lavori scientifici è attualmente di 2143.60 punti considerando l'I.F. più recente della rivista

I risultati delle ricerche finanziate dalla Associazione in questi anni sono stati presentati in numerosi convegni e congressi nazionali ed internazionali e pubblicati su importanti riviste scientifiche.
In patients with myelodysplastic syndromes (MDS), the likelihood of having a sustained response to azacitidine is increased by maximizing treatment duration. This is important
Background: The role of [¹⁸F] fluorodeoxyglucose (FDG)-positron emission tomography (PET) in follicular lymphoma (FL) staging is not yet determined. Patients and methods: The aim

86 – Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study

Male gender was recently reported as an adverse prognostic factor in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin,

85 – Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years

Breast cancer prognosis has improved greatly in recent years. Consequently, a thorough search for sensitive prognostic factors, able to help clinicians offer appropriate therapy,

82 – NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy

Objectives: Mantle cell lymphoma (MCL) is a distinct subtype of B-cell lymphoma; the complete response rate for standard therapies in use today is 85

81 – Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines

Less toxic and more active treatments are needed for indolent lymphomas as there is no curative treatment, and patients eventually die due to complications

80 – Prognosis and treatment of micrometastatic breast cancer sentinel lymph node: a population-based study

Background and Objectives: Major concern of sentinel lymph node (SLN) biopsy (SLNB) regards the prognosis of micrometastasis (Nmic) in SLN. The purpose of this

79 – Watchful Waiting in Low-Tumor Burden Follicular Lymphoma in the Rituximab Era: Results of an F2-Study Database

Purpose Patients with follicular lymphoma (FL) registered in the F2-study and initially managed without treatment were analyzed to describe the presentation and outcome of

76 – Collective evidence supports neutrality of BRCA1 V1687I, a novel sequence variant in the conserved THV motif of the first BRCT repeat

Unambiguous classification of BRCA1 and BRCA2 variants of uncertain significance (VUS) is a challenging task that vexes health care providers and has profound implications

75 – Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly “fit” patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi

We conducted a prospective study to compare epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab (R-miniCEOP) with cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab (R-CHOP) for the

74 – T-cell lymphomas in South America and Europe

Peripheral T-cell lymphomas are a group of rare neoplasms originating from clonal proliferation of mature post-thymic lymphocytes with different entities having specific biological characteristics

73 – Fertility in female survivors of Hodgkin’s lymphoma

Currently, Hodgkin’s lymphoma is one of the most curable types of cancer. Patients are often young and so the long-term morbidities of treatment have

72 – Genomic profiling of enzastaurin-treated B cell lymphoma RL cells

Follicular lymphoma (FL) is an indolent lymphoma associated with follicular centre B cells and typically contains the Bcl-2 chromosomal translocation t(14;18). FLs are sensitive

71 – Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial tretment of patients with mantle cell lymphoma: a multicentre trial from Gruppo Italiano Studio Linfomi.

This study investigated the clinical activity and toxicity of R-HCVAD-AM [rituximab plus HyperCVAD (R-HCVAD) alternating with high-dose cytarabine and methotrexate (AM)] in patients with
We conducted a population-based study to assess how positron emission tomography (PET) is currently used in patients with Hodgkin lymphoma (HL). Four cancer registries

69 – A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant

Several trials comparing the efficacy of standard melphalan and prednisone (MP) therapy with MP plus thalidomide (MPT) in elderly patients with multiple myeloma (MM)

68 – Risk for second malignancies in non-Hodgkin’s lymphoma survivors: a meta-analysis

Background: Late side-effects are becoming an important issue in non-Hodgkin’s lymphoma (NHL) survivors. We intended to estimate pooled relative risk (RR) of secondary malignant

67 – Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin’s lymphoma

Non-Hodgkin’s lymphoma (NHL) is the most common hematologic malignant neoplasm in adults [1]. Combination chemotherapy regimens have been the mainstay of treatment for NHL

66 – Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma

The effects of radiotherapy (RT) after chemotherapy in patients with diffuse large B-cell lymphoma (DLBCL) remain unclear; several trials have yielded conflicting results. This

65 – Protein expression patterns associated with advanced stage ovarian cancer

This is a comparative proteomic study on biopsies from patients with ovarian cancer to identify potential diagnostic/prognostic biomarkers in both healthy and tumor tissue,

64 – Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story

Background: Improved treatment have modified survival outcome in patients with diffuse large B-cell lymphoma (DLBCL) and altered the importance of previously recognized prognostic markers.

63 – Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL)

Indolent non-follicular non-Hodgkin lymphomas (INFL) are a heterogenous subset whose treatment has been poorly investigated. In this context we have evaluated the efficacy and

61- Favourable ten-year overall survival in a caucasian population with high probability of hereditary breast cancer

Background: The purpose of our study was to compare differences in the prognosis of breast cancer (BC) patients at high (H) risk or intermediate

62 – Effects of enzastaurin, alone or in combination, on signaling pathway controlling growth and survival of B-cell lymphoma cell lines

Immunochemotherapies have improved outcomes in indolent lymphoma. However, response durations progressively shorten following each treatment, and the majority of patients eventually die from the

60 – Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio Linfomi

We conducted a retrospective analysis on 168 adult patients with newly diagnosed, limited-stage (I and II) diffuse large B-cell lymphoma (DLBCL) treated from 1988

59 – Decreasing incidence of gastric MALT lymphomas in the era of anti-Helicobacter pylori interventions: results from a population-based study on extranodal marginal zone lymphomas

Background: Few studies have been carried out to date that have addressed the epidemiology of extranodal marginal zone lymphomas (EN-MZLs). Patients and methods: We

58 – Elongation Factor 1 alpha interacts with phospho-Akt in breast cancer cells and regulates their proliferation, survival and motility

Background: Akt/PKB is a serine/threonine kinase that has attracted much attention because of its central role in regulating cell proliferation, survival, motility and angiogenesis.

57 – Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project

Purpose The aim of the F2 study was to verify whether a prospective collection of data would enable the development of a more accurate

56 – Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: A GISL prospective era

Abstract:  Purpose: In the pre-positron emission tomography era, the Gruppo Italiano Studio Linfomi (GISL) investigated the feasibility and efficacy of a treatment based on

55 – ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin’s lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial

Purpose To compare doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) versus bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) versus cyclophosphamide, lomustine, vindesine, melphalan, prednisone,

54 – High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin’s lymphoma responding to front-line therapy: long-term results

No abstract available

53 – Identification of Protein Clusters Predictive of Response to Chemotherapy in Breast Cancer Patients

An attempt for the identification of potential biomarkers predictive of response to chemotherapy (CHT) in breast cancer patients has been performed by the use

52 – Second malignancies after treatment of diffuse large B-cell non-Hodgkin’s lymphoma: a GISL cohort study

Background Improved treatment has increased the life expectancy of patients with non-Hodgkin’s lymphoma, but few studies have addressed the issue of second cancer in

51 – The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines

Deregulation of the protein kinase C (PKC) signalling pathway has been implicated in tumor progression. Here we investigated the PKC inhibitor enzastaurin for its

49 – Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy

We conducted a population-based study of peripheral lymphomas (PL) that had been diagnosed between 1997 and 2003 in the province of Modena, Italy, with

46 – Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma

BACKGROUND. The current study was conducted to asses the safety profile and clinical activity of rituximab in combination with fludarabine and cyclophosphamide in patients

45 – Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients

BACKGROUND. It is unclear whether new treatment modalities have improved the survival of follicular lymphoma patients. Some data show that there has been no

44 – Long term results of a randomized study performed by Intergruppo italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuzse large B-cell lymphoma

The Intergruppo Italiano Linfomi started, in 1996, a randomized trial for the initial treatment of elderly patients (older than 65 years) with Diffuse Large

43 – Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients

Over a period of 28 months, we observed five cases of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates (BP) at

42 – Cancer incidence in eastern Libya: the first report from the Benghazi Cancer Registry, 2003

Cancer registration in Northern Africa is still limited and, until now, there have been no population-based data available for Libya. In this paper, we

41 – Prevalence of BRCA1 genomic rearrangements in a large cohort of Italian breast and breast/ovarian cancer families without detectable BRCA1 and BRCA2 point mutations

The presence of genomic rearrangements of the BRCA1 gene in breast and/or ovarian cancer families has been intensively investigated in patients from various countries



Tutti i nostri articoli pubblicati sulle riviste scientifiche


I progetti di ricerca che abbiamo sostenuto


Borse di studio e stage all'estero per ricercatori finanziati dall'Associazione


Premi di studio per la ricerca contro i tumori


Conferito ogni anno ad un illustre studioso che si è distinto nella lotta contro i tumori